GlassScriptPhysician profile
Janie Tran
NPI 1609122217
$2,024.76
in general payments reported to CMS, 2019-2025
21 companies · $590 in 2025
The $590 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $121 · 2021: $162 · 2022: $249 · 2023: $350 · 2024: $427 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,366.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $674.43 | 2022-2025 | Durysta |
| Oyster Point Pharma, INC. | $231.43 | 2022-2025 | Tyrvaya, Ryzumvi |
| Alcon Vision LLC | $225.17 | 2022-2025 | Rocklatan, Precision7, Eysuvis |
| Dompe US, INC. | $174.01 | 2024-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $135.84 | 2022-2025 | Miebo, Infuse, Envista Mx60 Iol |
| Sun Pharmaceutical Industries INC. | $123.84 | 2019-2021 | |
| Allergan, INC. | $75.39 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $55.19 | 2020 | |
| Harrow Eye, LLC | $37.24 | 2024-2025 | Vevye |
| Johnson & Johnson Vision Care, INC. | $36.24 | 2019-2021 | |
| Rxsight INC | $31.39 | 2022-2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Coopervision INC. | $31.35 | 2022-2024 | Clariti Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $29.07 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $26.52 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $24.07 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $21.96 | 2024 | Tepezza |
| Shire North American Group INC | $21.91 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $18.17 | 2024 | Xdemvy |
| Sight Sciences, INC. | $18.04 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.20 | 2020 | |
| Genentech USA, INC. | $16.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janie Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.